Clinical Trial Update: tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating tPA delivered via endovascular administration for submassive pulmonary embolism to reduce thrombus burden has completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Embolism

Drugs mentioned

• Endovascular tPA
• tPA (tissue plasminogen activator)

Snippet

Sponsor: Thrombolex, Inc. | Conditions: Pulmonary Embolism | Phase 3 | Status: COMPLETED | Results posted: 2023-04-20